Inhibikase Therapeutics reported that its Phase 2 trial of risvodetinib for untreated Parkinson's disease met safety and tolerability goals, but did not show significant efficacy improvements; the company will pause this program to focus on another treatment, IkT-001Pro, for pulmonary arterial hypertension.